MMedXYNews
Ask AIHomeVideos
MedXY AI/MedXY News/Section: Cardiology
Cardiology

Efficacy and Safety of Low-Dose Rivaroxaban in Advanced Chronic Kidney Disease with High Cardiovascular Risk: A Comprehensive Review

MedXY Editorial TeamSep 20, 2026
Rivaroxabananticoagulationcardiovascular riskbleeding

Highlights

  • Low-dose rivaroxaban does not reduce cardiovascular (CV) events in patients with advanced chronic kidney disease (CKD) at high CV risk.
  • Use of rivaroxaban in this population is associated with a significant increase in major bleeding events.
  • The balance between thrombotic risk reduction and bleeding risk remains challenging in advanced CKD.
  • Current evidence highlights the need for tailored anticoagulant strategies in advanced CKD beyond conventional approaches.

Background

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Assessing Cardiovascular Risk Prediction Models in Postmenopausal Women With Chronic Kidney Disease: Insights from the Women’s Health Initiative

CardiologyNov 3, 2026

Anticoagulation in Octogenarians with Atrial Fibrillation: Balancing Mortality Benefits and Bleeding Risks

CardiologyNov 4, 2026

Modulating Coronary Artery Calcification Progression: Insights from the DANCODE Trial on Vitamin K2 and D3 Supplementation

CardiologyNov 3, 2026
Loading comments...

Most read

  1. 01Intimate Health

    Five Benefits for Women Continuing Sexual Activity After Menopause

  2. 02Intimate Health

    Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It

  3. 03Nursing & care

    How often should a couple have sex?

  4. 04Cardiology

    Precision Medicine for Long QT Syndrome Type 2: Lumacaftor Corrects Trafficking Defects and Shortens QT Interval

  5. 05General Surgery

    Optimizing Postoperative Opioid Prescriptions After Intra-Abdominal Cancer Surgery: Comparing the 5x-Multiplier and 3-Tier Models

Go deeper with MedXY AI

Explore the evidence behind the news.

Ask AI
MedXY briefing

Stay informed

Medical news and research updates, delivered to your inbox.

© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story